BASF and Glycosyn leverage IP to successfully remove Glycom’s HMO products for IBS management from Amazon.com
BASF and Glycosyn announced its recent success in delisting Human Milk Oligosaccharide (HMO) products for Irritable Bowel Syndrome (IBS) applications from Amazon.com in the United States. BASF filed the infringements using the Amazon Utility Patent Neutral Evaluation Procedure1 based on Mehr